drugset
drugset / Trial / NCT06607692

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

NCT06607692 ↗

Phase 1/2 Recruiting 25 enrolled HM Hospitales
NaSingle-groupOpen-labelTreatment

Summary

Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)

Timeline

Start
2024-09-20
Primary completion
2029-07
Completion
2029-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 177Lu-DOTATATE Peptide 200 mbq/kg Intravenous
Subject 177Lu-DOTATATE Peptide 7400 mbq Intravenous
Subject Olaparib Small molecule 62.5 mg/m2 Oral
Subject Olaparib Small molecule 93.5 mg/m2 Oral
Subject Olaparib Small molecule 125 mg/m2 Oral
Subject Olaparib Small molecule 187.5 mg/m2 Oral

Indications

adrenal carcinoma diffuse intrinsic pontine glioma ependymoma esthesioneuroblastoma glioblastoma medulloblastoma meningioma neuroblastoma osteosarcoma paraganglioma pheochromocytoma pheochromocytoma-paraganglioma refractory malignant neoplasm synovial sarcoma